MAP3K7

Across TCGA pan-cancer cohorts, MAP3K7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP3K7 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP3K7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where MAP3K7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.561	0.890	<.001	52	view →
CCRCC	OS	Median	All	0.767	0.907	.023	5	view →
GBM	OS	Quartile	All	0.356	0.743	.003	4	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.669	.045	2	view →
HNSC	DFS	Quartile	II,III,IV	0.974	0.865	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP3K7–PDAC (DFS)

Open the PDAC breakdown →